Ftse Mib
35.398,82
-0,03%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.956,96
-0,18%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ PROCEPT BioRobotics Corporation (PRCT) PROCEPT BioRobotics Corporation (PRCT) Notizie

PRCT

PROCEPT BioRobotics (PRCT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PRCT
DataOraFonteTitoloSimboloCompagnia
13/05/202422:05GlobeNewswire Inc.PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock ConferenceNASDAQ:PRCTPROCEPT BioRobotics Corporation
08/05/202403:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRCTPROCEPT BioRobotics Corporation
06/05/202414:00GlobeNewswire Inc.Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic HyperplasiaNASDAQ:PRCTPROCEPT BioRobotics Corporation
04/05/202403:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PRCTPROCEPT BioRobotics Corporation
01/05/202413:00GlobeNewswire Inc.PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue GuidanceNASDAQ:PRCTPROCEPT BioRobotics Corporation
29/04/202414:00GlobeNewswire Inc.Late Breaking Abstract Presented at the Japanese Urological Association Annual Meeting on Aquablation Therapy Outcomes for Men in Japan with Lower Urinary Tract Symptoms due to Benign Prostatic HyperplasiaNASDAQ:PRCTPROCEPT BioRobotics Corporation
23/04/202414:00GlobeNewswire Inc.PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual MeetingNASDAQ:PRCTPROCEPT BioRobotics Corporation
04/04/202422:04GlobeNewswire Inc.PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, TexasNASDAQ:PRCTPROCEPT BioRobotics Corporation
02/04/202422:03GlobeNewswire Inc.PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024NASDAQ:PRCTPROCEPT BioRobotics Corporation
27/02/202422:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRCTPROCEPT BioRobotics Corporation
27/02/202422:02GlobeNewswire Inc.PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 ResultsNASDAQ:PRCTPROCEPT BioRobotics Corporation
12/02/202422:05GlobeNewswire Inc.PROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in BostonNASDAQ:PRCTPROCEPT BioRobotics Corporation
08/02/202423:30GlobeNewswire Inc.CTS Corporation Announces Appointment of Amy M. Dodrill to its Board of DirectorsNASDAQ:PRCTPROCEPT BioRobotics Corporation
08/01/202423:00GlobeNewswire Inc.PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 millionNASDAQ:PRCTPROCEPT BioRobotics Corporation
09/12/202302:01Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:PRCTPROCEPT BioRobotics Corporation
13/11/202322:03GlobeNewswire Inc.PROCEPT BioRobotics to Present at the 35ᵗʰ Annual Piper Sandler Healthcare Conference in New York CityNASDAQ:PRCTPROCEPT BioRobotics Corporation
02/11/202321:40Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRCTPROCEPT BioRobotics Corporation
01/11/202321:02GlobeNewswire Inc.PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue GuidanceNASDAQ:PRCTPROCEPT BioRobotics Corporation
16/10/202322:05GlobeNewswire Inc.PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023NASDAQ:PRCTPROCEPT BioRobotics Corporation
12/10/202314:00GlobeNewswire Inc.The National Institute for Health and Care Excellence Endorses Aquablation® Therapy with "Standard Arrangements" RecommendationNASDAQ:PRCTPROCEPT BioRobotics Corporation
20/09/202314:00GlobeNewswire Inc.PROCEPT BioRobotics Announces New Corporate Headquarters in San JoseNASDAQ:PRCTPROCEPT BioRobotics Corporation
12/09/202314:00GlobeNewswire Inc.PROCEPT BioRobotics® Receives U.S. FDA Investigational Device Exemption to Investigate Aquablation® Therapy for Prostate CancerNASDAQ:PRCTPROCEPT BioRobotics Corporation
22/08/202314:00GlobeNewswire Inc.PROCEPT BioRobotics® Announces First Commercial Aquablation Therapy Procedures in JapanNASDAQ:PRCTPROCEPT BioRobotics Corporation
17/08/202322:05GlobeNewswire Inc.PROCEPT BioRobotics to Present at the 2023 Wells Fargo Healthcare Conference in BostonNASDAQ:PRCTPROCEPT BioRobotics Corporation
16/08/202314:00GlobeNewswire Inc.NorthShore University HealthSystem offers expanded access to treat most common prostate ailmentNASDAQ:PRCTPROCEPT BioRobotics Corporation
03/08/202322:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRCTPROCEPT BioRobotics Corporation
02/08/202304:10GlobeNewswire Inc.PROCEPT BioRobotics Corporation Announces Pricing of Upsized Offering of Common StockNASDAQ:PRCTPROCEPT BioRobotics Corporation
01/08/202322:06GlobeNewswire Inc.PROCEPT BioRobotics Corporation Announces Proposed Offering of Common StockNASDAQ:PRCTPROCEPT BioRobotics Corporation
01/08/202322:01Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:PRCTPROCEPT BioRobotics Corporation
27/07/202313:00GlobeNewswire Inc.PROCEPT BioRobotics® Reports Second Quarter 2023 Financial Results and Increases 2023 Revenue GuidanceNASDAQ:PRCTPROCEPT BioRobotics Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PRCT

La tua Cronologia

COIN
LMCSWAPUSD
LIMOCOIN SWAP
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network